Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-? plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow…

Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (A?) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD patho…

Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.